Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567007 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1387143 | 0.93 | MTNR1B (0.89) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL1566122 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL338730 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29237 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29380213 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL29827337 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1612991 | 0.87 | MTNR1A (0.78) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566589 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL14863848 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | claimed |
| EP-1206943-B1 | MATRIX ADHERING TO NASAL MUCOSA | TAKEDA PHARMACEUTICAL (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | claimed |
| EP-1214944-B1 | Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | EP | claimed |
| US-6663883-B1 | Matrix adhering to the nasal mucosa which allows improved transfer into the brain of a drug, polyglycerol fatty acid ester, a viscogenic substance and (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-12-16 | — | — | US | claimed |
| EP-1214944-A1 | PERCUTANEOUS ABSORPTION AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | claimed |
| EP-1206943-A1 | MATRIX ADHERING TO NASAL MUCOSA | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | claimed |
| US-20210077431-A1 | N-(2-(SUBSTITUTED-NAPHTH-1-YL)ETHYL) SUBSTITUTED AMIDE COMPOUND, PREPARATION AND USES THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3653602-A1 | N-(2-(SUBSTITUTED-NAPHTH-1-YL)ETHYL) SUBSTITUTED AMIDE COMPOUND, PREPARATION AND USES THEREOF | Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) | 2020-05-20 | — | — | EP | disclosed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-1792899-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-07-09 | — | — | EP | disclosed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-6663883-B1 | Matrix adhering to the nasal mucosa which allows improved transfer into the brain of a drug, polyglycerol fatty acid ester, a viscogenic substance and (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-1214944-A1 | PERCUTANEOUS ABSORPTION AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | disclosed |
| EP-1206943-A1 | MATRIX ADHERING TO NASAL MUCOSA | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| JP-2002128773-A | TRICYCLIC COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE COMPOUND | TAKEDA CHEM IND LTD | 2002-05-09 | — | — | JP | disclosed |
| WO-2002016337-A1 | TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-28 | — | — | WO | disclosed |
| JP-2001131057-A | NASAL MUCOUS MEMBRANE-ADHERING MATRIX | TAKEDA CHEM IND LTD | 2001-05-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264521-A1 | Percutaneous absorption preparation | MTNR1A, MTNR1B, NPSR1 | MTNR1A 1/4885MTNR1B 2/4885ABCB11 166/4885 |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | MTNR1A 3487/4885MTNR1B 3104/4885ABCB11 108/4885 |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885ABCB11 3751/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | MTNR1A 3487/4885MTNR1B 3104/4885ABCB11 108/4885 |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885ABCB11 148/4885 |
| US-20210077431-A1 | N-(2-(SUBSTITUTED-NAPHTH-1-YL)ETHYL) SUBSTITUTED AMIDE COMPOUND, PREPARATION AND USES THEREOF | MTNR1A, HTR2C, MTNR1B | MTNR1A 1/4885MTNR1B 3/4885ABCB11 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.